PTX3 and aspergillosis: Prospective clinical trials are needed to confirm the results presented herein and to evaluate the possibility of discriminating between aspergillosis and mucormycosis by simultaneously analyzing biomarkers of host metabolism (Ptx3) and pathogen activity (siderophores), especially due to the small number of IPM patients in our study.